4.1 Acute Respiratory Failure & ARDS

Acute Respiratory Failure Overview

Acute respiratory failure is a critical condition defined by the inability of the respiratory system to maintain adequate gas exchange. It is broadly categorized into two primary types: Type I (hypoxemic) respiratory failure and Type II (hypercapnic) respiratory failure. The distinction between these two forms is essential for guiding diagnostic workup and targeted interventions in the acute care setting.

Type I Hypoxemic Respiratory Failure

Hypoxemic respiratory failure is characterized by a PaO2 less than 60 mm Hg on room air. The primary pathophysiologic mechanisms include ventilation-perfusion (V/Q) mismatch, intrapulmonary shunting, alveolar hypoventilation, diffusion impairment, and decreased inspired oxygen tension.

V/Q mismatch is the most common cause, frequently seen in conditions such as pneumonia, pulmonary embolism, asthma, and chronic obstructive pulmonary disease (COPD). An intrapulmonary shunt occurs when deoxygenated blood from the right side of the heart reaches the left side without participating in gas exchange. This is commonly observed in acute respiratory distress syndrome (ARDS), severe pneumonia, and pulmonary edema. Notably, hypoxemia caused by a true shunt does not correct significantly with the administration of supplemental oxygen, a hallmark that distinguishes it from V/Q mismatch.

Type II Hypercapnic Respiratory Failure

Hypercapnic respiratory failure is defined by a PaCO2 greater than 45 mm Hg in combination with acidemia (pH < 7.35). It results from alveolar hypoventilation due to decreased ventilatory drive, respiratory muscle fatigue, or increased dead space. Etiologies include central nervous system depression (e.g., opioid overdose, structural brain injury), neuromuscular disorders (e.g., Guillain-Barré syndrome, myasthenia gravis, ALS), and chest wall abnormalities (e.g., severe kyphoscoliosis, flail chest). Patients with severe asthma or COPD exacerbations may also present with Type II respiratory failure when they can no longer maintain the work of breathing required to overcome increased airway resistance, leading to progressive CO2 retention and respiratory acidosis.

Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of hypoxemic respiratory failure characterized by acute onset of severe hypoxemia, non-cardiogenic pulmonary edema, and decreased lung compliance. The pathophysiology involves an acute inflammatory response causing diffuse alveolar damage (DAD). This inflammatory cascade increases alveolar-capillary permeability, leading to the influx of protein-rich fluid, neutrophils, and erythrocytes into the alveolar space.

Etiology and Risk Factors

ARDS can be triggered by direct or indirect lung injury.

• Direct lung injury: Pneumonia (viral, bacterial, or fungal), aspiration of gastric contents, pulmonary contusion, inhalation injury, and near-drowning.
• Indirect lung injury: Sepsis (the most common cause of ARDS), severe trauma, massive transfusion, acute pancreatitis, and drug overdose.

The Berlin Definition of ARDS

Diagnosis relies on the Berlin criteria, which standardized the definition of ARDS and categorized its severity to predict mortality better and guide management strategies.

Severity Classification Based on P/F Ratio:

• Mild ARDS: 200 mm Hg < P/F ≤ 300 mm Hg
• Moderate ARDS: 100 mm Hg < P/F ≤ 200 mm Hg
• Severe ARDS: P/F ≤ 100 mm Hg

Management of ARDS

The management of ARDS focuses on treating the underlying cause, providing supportive care, and preventing further iatrogenic lung injury, particularly ventilator-induced lung injury (VILI).

Lung-Protective Ventilation Strategy

The cornerstone of ARDS management is lung-protective ventilation. This strategy utilizes low tidal volumes (Vt) to prevent volutrauma and appropriate Positive End-Expiratory Pressure (PEEP) to prevent atelectrauma (the repetitive opening and closing of alveoli).

• Target Tidal Volume: Initially set at 6 mL/kg of predicted body weight (PBW). It can be decreased to 4 mL/kg if plateau pressures remain high.
• Plateau Pressure Goal: Maintain plateau pressure (Pplat) ≤ 30 cm H2O to minimize barotrauma.
• Permissive Hypercapnia: Because low tidal volumes may lead to hypercapnia, a higher PaCO2 is tolerated (often maintaining pH ≥ 7.20-7.25) as a trade-off for lung protection. This is contraindicated in patients with elevated intracranial pressure.
• PEEP Management: Adequate PEEP is required to recruit collapsed alveoli, improve the V/Q ratio, and decrease intrapulmonary shunting. The ARDSNet lower and higher PEEP/FiO2 tables are commonly used to titrate PEEP in relation to oxygen requirements.

Adjunctive Therapies

When conventional lung-protective ventilation fails to adequately oxygenate the patient, several adjunctive therapies may be employed:

1. Prone Positioning: Placing the patient in the prone position for at least 16 hours per day has been shown to improve survival in patients with moderate to severe ARDS (P/F < 150). Proning improves V/Q matching by reducing pleural pressure gradients, leading to a more homogeneous distribution of ventilation and recruiting dependent, atelectatic lung regions without increasing airway pressures.
2. Neuromuscular Blockade (NMB): A short course (48 hours) of continuous NMB (e.g., cisatracurium) may be considered in early, severe ARDS to facilitate patient-ventilator synchrony, reduce oxygen consumption (VO2) by the respiratory muscles, and ensure strict adherence to lung-protective ventilation goals, though recent trials have debated its routine survival benefit over deep sedation alone.
3. Conservative Fluid Strategy: After initial resuscitation, a conservative fluid management strategy aims to achieve a neutral or slightly negative fluid balance. This reduces pulmonary edema and decreases the duration of mechanical ventilation and ICU length of stay without increasing the incidence of acute kidney injury.
4. Extracorporeal Membrane Oxygenation (ECMO): Venovenous (VV) ECMO may be considered for profound, refractory hypoxemia despite optimal conventional and adjunctive therapies (e.g., prone positioning). VV-ECMO provides gas exchange (oxygenation and CO2 removal) allowing for ultra-protective lung ventilation ("lung rest").

Prognosis and Long-Term Outcomes

While in-hospital mortality for severe ARDS remains high, survivors frequently experience significant long-term sequelae collectively termed Post-Intensive Care Syndrome (PICS). This includes profound physical deconditioning, ICU-acquired weakness, neurocognitive impairment (memory deficits, executive dysfunction), and psychological complications such as depression, anxiety, and post-traumatic stress disorder (PTSD). Pulmonary function typically improves over the first six months, but a mild reduction in diffusing capacity (DLCO) may persist for years.